Our acapreneurial strategy has enabled us to forge fruitful partnerships with biotechnology companies, including the following:
Currently on the market
Boehringer Ingelheim’s blood thinner dabigatran etexilate (Pradaxa®) was pioneered in clinical trials administered through LIMR. A collaboration funded by the company also promised to extend the drug’s use to cancer patients.
In preclinical development
Genisphere, LLC collaborated with LIMR in the development of a therapy targeting the mRNA-binding protein HuR using 3DNA nano-carriers for treating ovarian cancer. LIMR researchers also used the 3DNA nanotherapy to successfully deliver in a highly targeted fashion a low-dose treatment for rheumatoid arthritis, inserting the therapeutic directly into B cells in mice.
MYNARI Biomedical, Fort Washington, PA, is developing and commercializing MyNauseaRisk, a LIMR-developed blood assay that reliably and objectively predicts which cancer patients are most likely to experience acute nausea after chemotherapy.
OCMS Bio, LLC
OCMS Bio, LLC, Wynnewood, PA, is commercializing On-Cell mAb Screening (OCMS™), a novel technology developed at LIMR that produces monoclonal antibodies. It improves the standard technology in several ways: Most importantly it enables rapid identification and isolation of B cells that secrete antibodies with desired characteristics that can be challenging or impossible to obtain by existing methods.
Duet Therapeutics, Inc.
Duet Therapeutics, Inc., Princeton, NJ, is commercializing a set of LIMR-developed inventions to treat common, age-associated forms of blindness, including diabetic retinopathy and age-related macular degeneration.
IO Biotech is working with LIMR on a novel cancer vaccine methodology. Preclinical studies have shown that animals treated with the experimental approach not only had total remission of their cancers, but also showed complete protection against re-introduction of tumor cells. IO Biotech owns the intellectual property.
Dynamis Therapeutics, Inc.
Dynamis Therapeutics, Inc. is developing a small molecule drug for the treatment of diabetic complications and other autoimmune diseases. The drug was discovered in collaboration with LIMR scientists.
Telesis Therapeutics, LLC
Telesis Therapeutics is developing a small molecule cancer drug discovered at LIMR.
ProActive HealthSciences is developing a method to treat esophageal cancer based on studies done at LIMR.